In BMI's Q210 Pharmaceutical Business Environment Ratings (BER) matrix for Asia Pacific, Cambodia's immature pharmaceutical market is found in last position of the 16 markets surveyed within the region. One of the most recent additions to our pharmaceutical and healthcare universe, which already numbers in excess of 70 markets, Cambodia also ranks among the lowest on a global scale. The country's ranking is unlikely to improve significantly in the short term, given the negative influence of a combination of factors including the existence of counterfeiting activities, the population's low purchasing power and the lack of a national health insurance scheme. Moreover, given that it is flanked by the more advanced economies and thus more developed pharmaceutical markets of Thailand and Malaysia, Cambodia has ' to date ' largely been sidelined by multinationals that have sought to take advantage of emerging opportunities in non-Western countries. Although Cambodia's commitment to industrialisation and its receptiveness to foreign investment ' alongside encouraging demographic factors ' are sufficient to pique foreign interest in its pharmaceutical market, multinationals are likely to continue investing in less risky and more promising markets in the region. In the absence of comprehensive official data for industrial production, healthcare expenditure and spending on medicines ' among other statistics ' in most emerging markets, we have devised a new system for deriving at more accurate estimates for the value of a country's pharmaceutical market. We estimate that Cambodia's pharmaceutical spending at consumer prices was worth around US$172mn in 2009, with this figure based on calculations taking into account pharmaceutical exports and imports, as well as the country's wider economic performance. Through to 2014, we forecast that the market will grow at a compound annual growth rate (CAGR) of 12.09% in local currency terms, or 12.38% in US dollars, to reach the value of US$309mn. While Cambodia experienced a full-year recession in 2009 - its first since records began in the late 1980s - over the longer term, we continue to believe that the country can return to 7% real GDP growth, basing this belief on its economy's low base, favourable demographics, and natural resource wealth. However, such a scenario would be contingent on the authorities driving through substantial reform to boost infrastructure, improve governance and remain internationally competitive. Labour remains cheap and abundant, but less so than in Asian rivals Bangladesh and Myanmar. More worryingly, corruption, bureaucracy and poor infrastructure are all obstacles to long-term productivity and investment, which will also continue to have a negative effect on the development of the country's healthcare and pharmaceutical markets.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Cambodia Pharmaceuticals and Healthcare Report Q2 2010
Published on April 2010
Report Summary
In BMI's Q210 Pharmaceutical Business Environment Ratings (BER) matrix for Asia Pacific, Cambodia's immature pharmaceutical
market is found in last position of the 16 markets surveyed within the region. One of the most recent additions to our pharmaceutical
and healthcare universe, which already numbers in excess of 70 markets, Cambodia also ranks among the lowest on a global scale.
The country's ranking is unlikely to improve significantly in the short term, given the negative influence of a combination of factors
including the existence of counterfeiting activities, the population's low purchasing power and the lack of a national health insurance
scheme.
Moreover, given that it is flanked by the more advanced economies and thus more developed pharmaceutical markets of Thailand
and Malaysia, Cambodia has ' to date ' largely been sidelined by multinationals that have sought to take advantage of emerging
opportunities in non-Western countries. Although Cambodia's commitment to industrialisation and its receptiveness to foreign
investment ' alongside encouraging demographic factors ' are sufficient to pique foreign interest in its pharmaceutical market,
multinationals are likely to continue investing in less risky and more promising markets in the region.
In the absence of comprehensive official data for industrial production, healthcare expenditure and spending on medicines ' among
other statistics ' in most emerging markets, we have devised a new system for deriving at more accurate estimates for the value of a
country's pharmaceutical market. We estimate that Cambodia's pharmaceutical spending at consumer prices was worth around
US$172mn in 2009, with this figure based on calculations taking into account pharmaceutical exports and imports, as well as the
country's wider economic performance. Through to 2014, we forecast that the market will grow at a compound annual growth rate
(CAGR) of 12.09% in local currency terms, or 12.38% in US dollars, to reach the value of US$309mn.
While Cambodia experienced a full-year recession in 2009 - its first since records began in the late 1980s - over the longer term, we
continue to believe that the country can return to 7% real GDP growth, basing this belief on its economy's low base, favourable
demographics, and natural resource wealth. However, such a scenario would be contingent on the authorities driving through
substantial reform to boost infrastructure, improve governance and remain internationally competitive. Labour remains cheap and
abundant, but less so than in Asian rivals Bangladesh and Myanmar. More worryingly, corruption, bureaucracy and poor infrastructure
are all obstacles to long-term productivity and investment, which will also continue to have a negative effect on the development of the
country's healthcare and pharmaceutical markets.
Table of Content
Executive Summary .6
SWOT Analysis 7
Cambodia Pharmaceuticals And Healthcare Industry SWOT . 7
Pharmaceutical Business Environment Ratings . 8
Table: Asia Pacific Pharmaceutical Business Environment Ratings, Q210 ...... 8
Limits to Potential Returns ..... 9
Risks to Realisation of Returns ........ 9
Cambodia - Market Summary . 11
Historical Data & Forecasts . 11
Regulatory Regime . 12
Cambodia Pharmaceuticals and Healthcare Report Q2 2010 Page 1/4

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Intellectual Property Environment . 12
Counterfeit Medicine ... 13
Pricing and Reimbursement .. 14
Industry Trends and Developments ........ 15
Epidemiology ........ 15
Healthcare Sector . 16
Health Insurance .. 17
Pharmaceutical Wholesale ... 17
Pharmaceutical Retail . 17
Research And Development Sector 18
Clinical Trials ....... 19
Medical Devices .... 19
Industry Forecast Scenario .... 20
Pharmaceutical Market Forecast .. 20
Healthcare Market Forecast . 21
Key Growth Factors - Macroeconomic .. 22
Pharmaceutical Trade Forecast .... 25
Key Risks to BMI's Forecast Scenario ... 26
Competitive Landscape .. 27
Pharmaceutical Industry ....... 27
Recent Pharmaceutical Company Developments 28
Company Profiles ... 30
Indigenous Companies ...... 30
PharmaProduct Manufacturing (PPM) . 30
Cambodia Pharmaceutical Enterprises (CPE) ... 32
Multinational Companies .. 33
Sanofi-Aventis ....... 33
Pfizer ........ 34
Country Snapshot: Cambodia Demographic Data ... 35
Section 1: Population ... 35
Table: Demographic Indicators, 2005-2030 ... 35
Table: Rural/Urban Breakdown, 2005-2030 .. 36
Section 2: Education And Healthcare .... 36
Table: Education, 2002-2005 ........ 36
Table: Vital Statistics, 2005-2030 .. 36
Section 3: Labour Market And Spending Power . 37
Table: Employment Indicators, 2000-2004 ..... 37
Table: Consumer Expenditure, 2000-2009 (US$mn) ... 37
Table: Average Annual Manufacturing Wages, 1996-2001 .. 38
BMI Methodology ... 39
How We Generate Our Pharmaceutical Industry Forecasts ...... 39
Pharmaceutical Business Environment Ratings Methodology ... 40
Ratings Overview .. 40
Table: Pharmaceutical Business Environment Indicators .... 41
Weighting .. 42
Table: Weighting Of Components .. 42
Sources . 42
Forecast Tables ...... 43
Cambodia Pharmaceuticals and Healthcare Report Q2 2010 Page 2/4

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Cambodia Pharmaceuticals and Healthcare Report Q2 2010
Product Formats
Please select the product formats and the quantity you require.
Digital Copy--USD 530.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Cambodia Pharmaceuticals and Healthcare Report Q2 2010 Page 3/4

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Cambodia Pharmaceuticals and Healthcare Report Q2 2010 Page 4/4